Abstract
The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Current Drug Targets
Title:Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis
Volume: 14 Issue: 6
Author(s): Xuli Zhao, Ye Yue, Wengxiang Cheng, Jingchao Li, Yiping Hu, Ling qin and Peng Zhang
Affiliation:
Keywords: Angiogenesis, hypoxia-inducible factor, rheumatoid arthritis, regulation, tumor therapy, therapeutic target.
Abstract: The hypoxic microenvironment is a clinicopathological characteristic of many diseases, such as rheumatoid arthritis (RA). As a transcription factor activating the gene expression involved in processes such as cell metabolism and angiogenesis, hypoxia-inducible factor (HIF) has a central function in adaption to altered oxygen tension and even contributes to the progression of related diseases. In RA, HIF induces angiogenesis, cell migration, and cartilage destruction, inhibits the apoptosis of synovial cells and inflammatory cells and initiates glycolysis for energy supply by upregulating specific protein levels. HIF expression in RA can be regulated in both oxygen-dependent and independent fashions, leading to the aggravation of this disease. Therefore, HIF is one of the vital RA mediators. Based on the application of HIFtargeted drug research and development in tumors, HIF is a potential therapeutic target for treating RA.
Export Options
About this article
Cite this article as:
Zhao Xuli, Yue Ye, Cheng Wengxiang, Li Jingchao, Hu Yiping, qin Ling and Zhang Peng, Hypoxia-Inducible Factor: A Potential Therapeutic Target for Rheumatoid Arthritis, Current Drug Targets 2013; 14 (6) . https://dx.doi.org/10.2174/1389450111314060010
DOI https://dx.doi.org/10.2174/1389450111314060010 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Innate Immune System and Fever under Redox Control: A Narrative
Review
Current Medicinal Chemistry Restless Legs Syndrome in Children: A Review and Update on Pharmacological Options
Current Pharmaceutical Design Branched-Chain Amino Acids and Pigment Epithelium-Derived Factor: Novel Therapeutic Agents for Hepatitis C Virus-Associated Insulin Resistance
Current Medicinal Chemistry Radiolabelled Probes Targeting Infection and Inflammation for Personalized Medicine
Current Pharmaceutical Design Leukotriene C4 Synthase: Upcoming Drug Target For Inflammation
Current Drug Targets Evaluation of in vivo Anti-inflammatory and Analgesic Activities of Novel Derivatives of Ugi-4CR
Mini-Reviews in Medicinal Chemistry Bioactive Triterpenic Acids: From Agroforestry Biomass Residues to Promising Therapeutic Tools
Mini-Reviews in Organic Chemistry The Effect of Apium Nodiflorum in Experimental Osteoporosis
Current Pharmaceutical Biotechnology New Achievements in Bioinformatics Prediction of Post Translational Modification of Proteins
Current Topics in Medicinal Chemistry Metal-Based Antimicrobial Protease Inhibitors
Current Medicinal Chemistry Pulmonary Arterial Hypertension: Need to Treat
Inflammation & Allergy - Drug Targets (Discontinued) Selenium and Selenoproteins: An Overview on Different Biological Systems
Current Protein & Peptide Science Advances in Clinical Study of Curcumin
Current Pharmaceutical Design RAGE Signaling in Cell Adhesion and Inflammation
Current Pediatric Reviews Chemoprevention of Cancers in Gastrointestinal Tract with Cyclooxygenase 2 Inhibitors
Current Pharmaceutical Design Patent Selections
Recent Patents on Nanomedicine Pro-Inflammatory Mechanisms in Diabetic Neuropathy: Focus on the Nuclear Factor Kappa B Pathway
Current Drug Targets Role of Cytokines in the Pathophysiology of Acute Graft-Versus-Host Disease (GVHD)– Are Serum/Plasma Cytokines Potential Biomarkers for Diagnosis of Acute GVHD Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)?
Current Stem Cell Research & Therapy Predictive Factors for Disability as Evaluated by the Health Assessment Questionnaire in Rheumatoid Arthritis: A Literature Review
Inflammation & Allergy - Drug Targets (Discontinued) Bacterial Urease and its Role in Long-Lasting Human Diseases
Current Protein & Peptide Science